Ventyx Biosciences Presents VTX002 Phase 2 Ulcerative Colitis Trial Results at ECCO Congress

Ventyx Biosciences, a pharmaceutical firm, has announced the presentation of Phase 2 trial data for their drug VTX002, which is being developed to treat ulcerative colitis. The data will be unveiled at the European Crohn's and Colitis Organisation's 19th Congress in Stockholm, Sweden, on February 22, 2024.

The company's CEO, Raju Mohan, expressed enthusiasm for the opportunity to showcase the findings of the VTX002 trial, highlighting the drug's promising efficacy and safety profile. He emphasized the potential of VTX002 to offer a superior oral treatment option for ulcerative colitis patients, with a unique rate of endoscopic remission and histologic-endoscopic mucosal improvement.

The oral presentation at the conference will be led by Dr. Bruce E. Sands, a prominent figure in gastroenterology from the Icahn School of Medicine at Mount Sinai, New York. The session will delve into the efficacy and safety of VTX002, a selective sphingosine-1-phosphate-1 receptor modulator, in treating patients with moderately to severely active ulcerative colitis.

Following the presentation, the company plans to make the slides available on their website for further review by interested parties. Ventyx Biosciences is dedicated to the development of innovative oral treatments for autoimmune and inflammatory disorders. The company's pipeline includes several clinical programs targeting different pathways, with the aim of transforming the immunology market by shifting from injectable to oral drug therapies.

Headquartered in San Diego, California, Ventyx Biosciences is poised to become a leader in oral immunology therapies, with a focus on delivering novel treatments that address significant unmet medical needs. The company's commitment to advancing their pipeline and the potential of VTX002 in ulcerative colitis underscores their mission to improve patient outcomes and contribute to the field of inflammatory disease management.